TẠP CHÍ KHOA HỌC YERSIN
YERSIN JOURNAL OF SCIENCE
ISSN: 2525 - 2372
TẠP CHÍ KHOA HỌC YERSIN
YERSIN JOURNAL OF SCIENCE
Thừa cân và béo phì là vấn đề lớn trên toàn cầu. Thừa cân và béo phì gây ra làm tăng nguy cơ mắc đái tháo đường type 2 và bệnh tim mạch, cũng như nhiều bệnh mãn tính khác. Việc giảm cân ở người thừa cân béo phì đem lại lợi ích cho sức khỏe. Thay đổi lối sống lành mạnh được khuyến nghị là nền tảng của việc quản lý bệnh béo phì. Thuốc được sử dụng trong trường hợp thay đổi lối sống không hiệu quả ở bệnh nhân béo phì hoặc BMI ≥ 27 kg/m2 có kèm bệnh mãn tính. Hiện tại, có một số thuốc được Cục quản lý Thực phẩm và Dược phẩm Hoa Kỳ phê duyệt để giảm cân là orlistat, liraglutid, semaglutid, tirzepatid, diethylpropion, phentermine, phentermine/topiramat và bupropion/naltrexon và 1 thiết bị là Gelesis100. Bài tổng quan này nhằm đề cập đến các thuốc và thiết bị được sử dụng để giảm cân, ưu nhược điểm của thuốc trong lâm sàng.
Overweight and obesity are a major problem globally. Being overweight and obese increases the risk of type 2 diabetes and cardiovascular disease, as well as many other chronic diseases. Weight loss in overweight and obese people brings health benefits. Healthy lifestyle changes are recommended as the foundation of obesity management. The drug is used in cases where lifestyle changes are ineffective in patients with obesity or BMI ≥ 27 km/m2 with chronic diseases. Currently, there are a number of drugs approved by the US Food and Drug Administration for weight loss: orlistat, liraglutide, semaglutide, tirzepatid, diethylpropion, phentermine, phentermine/topiramate and bupropion/naltrexon, and 1 device is Gelesis100. This review covers drugs and devices used for weight loss, providing a summary of their relevant characteristics, clinical advantages, and disadvantages.
thừa cân, béo phì, giảm cân, thuốc giảm cân, thuốc điều trị béo phì
overweight, obesity, weight loss, weight loss medication, anti - obesity medication
Aldekhail, N. M., Logue, J., McLoone, P., & Morrison, D. S. (2015). Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev, 16(12), 1071-1080. doi:10.1111/obr.12318
Aronne, L. J., Hall, K. D., J, M. J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021). Describing the Weight-Reduced State: Physiology, Behavior, and Interventions. Obesity (Silver Spring), 29 Suppl 1(Suppl 1), S9-s24. doi:10.1002/oby.23086
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., . . . Murphy, M. A. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Jama, 331(1), 38-48. doi:10.1001/jama.2023.24945
Bhattad, P. B., Arun Kumar, P., Dasari, M., Sherif, A. A., Mishra, A. K., & Filiberti, A. W. (2023). Dilated Cardiomyopathy: Beware of Diet Drugs Slimming the Heart. Cureus, 15(3), e36874. doi:10.7759/cureus.36874
Bracamontes-Castelo, G., Bacardí-Gascón, M., & Jiménez Cruz, A. (2019). Effect of water consumption on weight loss: a systematic review. Nutr Hosp, 36(6), 1424-1429. doi:10.20960/nh.02746
Chen, Q. Y., Khil, J., & Keum, N. (2024). Water Intake and Adiposity Outcomes among Overweight and Obese Individuals: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 16(7). doi:10.3390/nu16070963
Çıtar Dazıroğlu, M. E., & Acar Tek, N. (2023). Water Consumption: Effect on Energy Expenditure and Body Weight Management. Curr Obes Rep, 12(2), 99-107. doi:10.1007/s13679-023-00501-8
Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C. (2012). The FDA's assessment of two drugs for chronic weight management. N Engl J Med, 367(17), 1577-1579. doi:10.1056/NEJMp1211277
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023). Obesity Management in Adults: A Review. Jama, 330(20), 2000-2015. doi:10.1001/jama.2023.19897
Fruh, S. M. (2017). Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract, 29(S1), S3-s14. doi:10.1002/2327-6924.12510
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol, 13, 935823. doi:10.3389/fphar.2022.935823
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. (2020). Lancet, 396(10258), 1223-1249. doi:10.1016/s0140-6736(20)30752-2
Goldenberg, R. M., & Steen, O. (2019). Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Can J Diabetes, 43(2), 136-145. doi:10.1016/j.jcjd.2018.05.008
Greenway, F. L., Aronne, L. J., Raben, A., Astrup, A., Apovian, C. M., Hill, J. O., . . . Heshmati, H. M. (2019). A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring), 27(2), 205-216. doi:10.1002/oby.22347
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., . . . Davitkov, P. (2022). AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology, 163(5), 1198-1225. doi:10.1053/j.gastro.2022.08.045
Guerciolini, R. (1997). Mode of action of orlistat. Int J Obes Relat Metab Disord, 21 Suppl 3, S12-23.
Haslam, D. (2016). Weight management in obesity - past and present. Int J Clin Pract, 70(3), 206-217. doi:10.1111/ijcp.12771
Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000). Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 20(3), 270-279. doi:10.1592/phco.20.4.270.34882
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., . . . Metz, A. (2002). Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res, 10(10), 1049-1056. doi:10.1038/oby.2002.142
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., . . . Pi-Sunyer, X. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, 389(10077), 1399-1409. doi:10.1016/s0140-6736(17)30069-7
Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., . . . Arterburn, D. E. (2019). Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity (Silver Spring), 27(4), 591-602. doi:10.1002/oby.22430
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., . . . Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24), 2221-2232. doi:10.1056/NEJMoa2307563
Lucchetta, R. C., Riveros, B. S., Pontarolo, R., Radominski, R. B., Otuki, M. F., Fernandez-Llimos, F., & Correr, C. J. (2017). Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics (Sao Paulo), 72(5), 317-324. doi:10.6061/clinics/2017(05)10
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., . . . Buse, J. B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 375(4), 311-322. doi:10.1056/NEJMoa1603827
Nagendra, L., Bg, H., Sharma, M., & Dutta, D. (2023). Semaglutide and cancer: A systematic review and meta-analysis. Diabetes Metab Syndr, 17(9), 102834. doi:10.1016/j.dsx.2023.102834
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., . . . Smith, S. R. (2016). Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. Jama, 315(10), 990-1004. doi:10.1001/jama.2016.1558
Nwayyir, H. A., Mutasher, E. M., Alabid, O. M., Jabbar, M. A., Abdulraheem Al-Kawaz, W. H., Alidrisi, H. A., . . . Khazaal, F. A. K. (2023). Recommendations for the prevention and management of obesity in the Iraqi population. Postgrad Med, 135(5), 425-439. doi:10.1080/00325481.2023.2172914
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., . . . Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 392(10148), 637-649. doi:10.1016/s0140-6736(18)31773-2
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., . . . St-Onge, M. P. (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 143(21), e984-e1010. doi:10.1161/cir.0000000000000973
Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep, 6(2), 187-194. doi:10.1007/s13679-017-0262-y
Sahebkar, A., Simental-Mendía, L. E., Reiner, Ž., Kovanen, P. T., Simental-Mendía, M., Bianconi, V., & Pirro, M. (2017). Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res, 122, 53-65. doi:10.1016/j.phrs.2017.05.022
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab, 31(6), 410-421. doi:10.1016/j.tem.2020.02.006
Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022). Tirzepatide-Friend or Foe in Diabetic Cancer Patients? Biomolecules, 12(11). doi:10.3390/biom12111580
Singh, A. K., & Singh, R. (2020). Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol, 13(1), 53-64. doi:10.1080/17512433.2020.1698291
Singh, J., & Kumar, R. (2015). Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res, 5(2), 157-158. doi:10.4103/2229-516x.157177
Sposito, A. C., Bonilha, I., Luchiari, B., Benchimol, A., Hohl, A., Moura, F., . . . Carvalho, L. S. F. (2021). Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obes Rev, 22(6), e13224. doi:10.1111/obr.13224
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., . . . Wicklum, S. (2020). Obesity in adults: a clinical practice guideline. Cmaj, 192(31), E875-e891. doi:10.1503/cmaj.191707
Administration, U. S. F. a. D. (2023). MOUNJARO®(tirzepatide) Injection.
American Diabetes Association Professional Practice, C. (2023). 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024. Diabetes Care, 47(Supplement_1), S145-S157. doi:10.2337/dc24-S008
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., . . . Zdravkovic, M. (2010). Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. Endocrinology, 151(4), 1473-1486. doi:10.1210/en.2009-1272
European Medicines Agency. (2023). Amfepramone-containing medicinal products - referral.
Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., . . . Cowley, M. A. (2009). Rational Design of a Combination Medication for the Treatment of Obesity. Obesity, 17(1), 30-39. doi:https://doi.org/10.1038/oby.2008.461
Liu, Y., Han, F., Xia, Z., Sun, P., Rohani, P., Amirthalingam, P., & Sohouli, M. H. (2024). The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 16(1), 93. doi:10.1186/s13098-024-01319-7
Miller, L. E., & Bhattacharyya, R. (2019). Unclear Benefit of Gelesis100 for Body Weight Loss. Obesity, 27(9), 1383-1383. doi:https://doi.org/10.1002/oby.22532
Onakpoya, I. J., Lee, J. J., Mahtani, K. R., Aronson, J. K., & Heneghan, C. J. (2020). Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology, 86(4), 646-667. doi:https://doi.org/10.1111/bcp.14210
Pass, A., Bialonczyk, D., Chiquette, E., & Goldman, J. D. (2020). Oral Superabsorbent Hydrogel (Plenity) for Weight Management. Annals of Pharmacotherapy, 55(9), 1146-1152. doi:10.1177/1060028020983046
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., . . . Ueda, P. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ, 385, e078225. doi:10.1136/bmj-2023-078225
Popovic, D. S., Patoulias, D., Popovic, L. S., Karakasis, P., Papanas, N., & Mantzoros, C. S. (2024). Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 213, 111758. doi:https://doi.org/10.1016/j.diabres.2024.111758
U.S. Food and Drug Administration. (2012). Adipex-p (phentermine hydrochloride) capsules label. Truy cập ngày 18/7/2024, từ https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf
U.S. Food and Drug Administration. (2018). De Novo classification request for Plenity. Truy cập ngày 18/7/2024, từ https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180060.pdf
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., . . . Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2909-2918. doi:10.1038/s41591-023-02597-w
World Health Organization. (01.03.2024). Obesity and overweight. Truy cập ngày 18/7/2024, từ https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight